康柏西普辅助治疗新生血管性青光眼手术的临床疗效及组织病理学观察

背景 新生血管性青光眼(NVG)是眼部缺血性疾病引起的继发性青光眼,抗血管内皮生长因子药物,如贝伐单抗、雷珠单抗治疗NVG是安全、有效的,但康柏西普的治疗效果有待进一步研究. 目的 观察玻璃体腔注射康柏西普联合小梁切除术及全视网膜光凝术治疗NVG的有效性及安全性. 方法 前瞻性、干预性病例研究.连续收集2015年5月至2016年5月于天津市眼科医院确诊的NVG患者26例27眼,其中25眼先行玻璃体腔注射康柏西普,再行小梁切除术及全视网膜光凝术,分别于术前及术后不同时间点行最佳矫正视力(LogMAR)、眼压及相关治疗手段的检测,观察术后并发症,对术中所得小梁及虹膜组织行光学显微镜及透射电子显微镜观察;2眼行眼球摘除术,术后眼球组织行光学显微镜观察作为病理对照.结果术后随访至6个月时,行玻璃体腔注药联合小梁切除术的25眼眼压从(48.8±.10.2)mmHg(1 mmHg=0.133 kPa)降至(18.0±4.3) mmHg,抗青光眼药物使用数量从3.0(3.0,4.0)降至0.0(0.0,1.0),差异均有统计学意义(均P＜0.05);最佳矫正视力(LogMAR)从2.0±0.9提高至1.5±1.4,差异无统计学意义(P＞0.05).术后21眼眼压≤21 mmHg,手术成功,4眼手术失败.行玻璃体腔注药后光学显微镜下可见虹膜表面新生血管明显消退,虹膜前基质层可见薄壁血管;透射电子显微镜下可见虹膜前基质层血管数量减少,可见闭塞或空腔血管,血管内皮细胞变性.结论 NVG患者行玻璃体腔注射康柏西普可使虹膜表面新生血管回退,并发症减少,联合小梁切除术及全视网膜光凝术可有效控制眼压及保存视功能.

Adjuvant treatment of neovascular glaucoma with conbercept: clinical efficacy and histopathological analysis of trabeculectomy specimens

Background Neovascular glaucoma (NVG) often occurs secondary to ocular ischemic diseases.Intravitreal injection of bevacizumab or ranibizumab as an adjunct therapy or NVG is safe and efficient.However,the efficacy of intravitreal injection of conbercept for NVG is still under exploration.Objective This study was to evaluate the efficacy and safety of intravitreal conbercept combined with trabeculectomy and panretinal photocoagulation for NVG.Methods A prospective,interventional case series study was performed.Twenty-six patients (27 eyes) who were diagnosed with NVG in Tianjin Eye Hospital were included.Twenty-five eyes were initially injected with conbercept into vitreous,then trabeculectomy and panretinal photocoagulation were performed,the best corrected visual acuity (LogMAR),intraocular pressure and treatment-related indexes were examined before and after treatment,the intraoperative and postoperative complications were evaluated.Light microscopy and transmission electron microscopy were used to observe the surgically excised trabecular tissue.Enucleation was performed on 2 eyes,and the surgically excised tissue was taken as the histopathological controls.Results At six monthes after surgery,the intraocular pressure of the 25 patients with intravitreal injection of conbercept were decreased from (48.8 ± 10.2) mmHg to (18.0±4.3) mmHg,the number of anti-glaucoma medications were decreased from 3.0 (3.0,4.0) to 0.0 (0.0,1.0) (both at P＜0.05).Best corrected visual acuity (LogMAR) was increased from 2.0± 0.9 to 1.5 ± 1.4 (P＞0.05).Twenty-one eyes displayed controlled intraocular pressure (≤ 21 mmHg) after treatment.Regression of neovasculariztion in the surface of iris and thin-walled vessels in the iris stroma in specimens with intravitreal injection of conbercept were revealed by light microscopy.New vessels decreased,endothelial cell degeneration and vascular occlusion or cavity in the iris stroma in the conbercept-treatment specimens were revealed by transmission electron microscopy.Conclusions A comprehensive therapy for NVG can regress iris neovascularization,reduce postoperative complication,effectively control intraocular pressure and preserve visual function by intravitreal injection of conbercept,anti-glaucoma surgery and panretinal photocoagulation.